查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566962

人工胰臟設備系統市場：按設備類型、最終用戶分類：2024-2033 年全球機會分析與產業預測

Artificial Pancreas Devices Systems Market By Device Type (Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems), By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，人工胰臟裝置系統市值為4億美元，預計2024年至2033年複合年成長率為8.8%，到2033年將達到8億美元。

人工胰臟裝置是醫療設備，旨在維持最佳血糖值。這項醫療技術主要旨在監測和調節糖尿病患者（尤其是第 1 型糖尿病患者）的血糖值。這些設備旨在恢復失去的功能、提高人類表現並提高整體生活品質。

人工胰臟設備系統市場的成長主要是由於全球糖尿病（尤其是 1 型糖尿病）盛行率的驚人成長，以及患者和醫療保健提供者對人工胰臟設備系統益處的認知不斷提高而推動的。根據 2021 年第 10 版 IDF 糖尿病圖譜的主要發現，大約有 5.37 億成年人患有糖尿病。預計到 2030 年，這一數字將達到 6.43 億，到 2045 年將達到 7.83 億。據報道，2021年約有670萬人死於糖尿病。此外，醫療保健支出的增加，尤其是在新興國家，正在使更多患者能夠使用先進的糖尿病管理技術。據同一資訊來源稱，2021 年糖尿病導致的醫療保健支出至少為 9,660 億美元。此外，人工胰臟設備系統與數位健康平台和智慧型手機應用程式的整合將增強病人參與，實現更好的遠端監控和管理，並成為市場的關鍵驅動力。然而，人工胰臟裝置系統的高成本限制了市場的成長。此外，大多數國家缺乏足夠的醫療保健設施來滿足人口的需求，而且訪問管道有限，也是市場的主要阻礙因素。相反，感測器技術、胰島素輸送系統和控制演算法的不斷改進預計將提高人工胰臟設備系統的性能和可靠性，並在預測期內為全球市場擴張提供利潤豐厚的機會。此外，越來越多旨在改善糖尿病護理和管理的舉措正在獎勵人工胰腺設備系統的採用。例如，世界衛生組織於 2021 年 4 月推出了舉措。該舉措旨在降低糖尿病的風險，並確保糖尿病患者能夠獲得負擔得起的優質治療和護理。

人工胰臟設備系統產業分為設備類型、最終用戶和地區。按設備類型分類，市場分為閾值暫停設備系統、控制範圍 (CTR) 系統和控制目標 (CTT) 系統。依最終使用者分為醫院、診所、居家醫療。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按設備類型分類，閾值暫停設備系統細分市場將在 2023 年佔據市場佔有率。

按最終用戶分類，居家照護細分市場將在 2023 年獲得最大佔有率。

按地區分類，2023年北美將佔據市場主導地位。

可以自訂此報告（需要額外的費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章人工胰臟設備系統市場：依設備類型

  • 市場概況
  • 閾值暫停裝置系統
  • 範圍控制 (CTR) 系統
  • 目標控制（CTT）系統

第5章人工胰臟設備系統市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 診所
  • 居家醫療

第6章人工胰臟設備系統市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國人工胰臟裝置系統市場
    • 加拿大人工胰臟裝置系統市場
    • 墨西哥人工胰臟裝置系統市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國人工胰臟裝置系統市場
    • 法國人工胰臟裝置系統市場
    • 英國人工胰臟裝置系統市場
    • 義大利人工胰臟裝置系統市場
    • 西班牙人工胰臟裝置系統市場
    • 其他歐洲人工胰臟裝置系統市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本人工胰臟裝置系統市場
    • 中國人工胰臟器材系統市場
    • 澳洲人工胰臟裝置系統市場
    • 印度人工胰臟裝置系統市場
    • 韓國人工胰臟裝置系統市場
    • 其他亞太人工胰臟設備系統市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西人工胰臟裝置系統市場
    • 沙烏地阿拉伯人工胰臟裝置系統市場
    • 南非人工胰臟裝置系統市場
    • 其他拉丁美洲/中東/非洲人工胰臟裝置系統市場

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • Medtronic Plc
  • Bigfoot Biomedical, Inc.
  • Johnson And Johnson
  • Tandem Diabetes Care, Inc.
  • Pancreum, Inc
  • TypeZero Technologies, LLC
  • Beta Bionics, Inc
  • Insulate Corporation
  • Diabeloop
  • Inreda Diabetic
簡介目錄
Product Code: A324367

The artificial pancreas devices systems market was valued at $0.4 billion in 2023, and is projected to reach $0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.

Artificial pancreas device is a medical device that mimics the glucose-regulating function of a healthy pancreas, aiming to maintain optimal blood sugar levels. This medical technology is primarily designed to monitor and regulate blood glucose levels in individuals suffering from diabetes, particularly those with type 1 diabetes. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life.

The growth of the artificial pancreas devices systems market is majorly driven by alarming increase in global prevalence of diabetes, particularly type 1 diabetes and rise in awareness among patients and healthcare providers about the benefits of artificial pancreas systems. According to the 2021 key findings of IDF Diabetes Atlas 10th edition, approximately 537 million adults are suffering diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045. Around 6.7 million deaths were reported due to diabetes in 2021. Moreover, increase in healthcare expenditure, particularly in emerging economies, allows more patients to access advanced diabetes management technologies. As per the same source, diabetes was responsible for at least $966 billion dollars in health expenditure in 2021. Furthermore, the integration of artificial pancreas devices systems with digital health platforms and smartphone applications enhances patient engagement and allows for better remote monitoring and management, which acts as the key driving force of the market. However, high cost associated with the artificial pancreas devices systems restrains the growth of the market. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, continuous improvements in sensor technology, insulin delivery systems, and control algorithms enhance the performance and reliability of artificial pancreas systems, which are expected to offer remunerative opportunities for the expansion of the global market during the forecast period. In addition, increase in initiatives aimed at improving diabetes care and management are providing incentives for the adoption of artificial pancreas systems. For instance, the World Health Organization launched an initiative in April 2021, WHO Global Diabetes Compact. The initiative aims to reduce the risk of diabetes and ensure that diabetic individuals have access to affordable and quality treatment and care.

The artificial pancreas devices systems industry is segmented into device type, end user, and region. By device type, the market is divided into threshold suspend device systems, control-to-range (CTR) systems, and control-to-target (CTT) systems. On the basis of end user, it is divided into hospitals, clinics, homecare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By device type, the threshold suspend device systems segment dominated the market, in terms of share, in 2023.

Depending on end user, the homecare segment captured the largest share in 2023.

Region wise, North America holds a dominant position in the market in 2023.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial pancreas devices systems market include Medtronic plc, Bigfoot Biomedical, Inc., Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc, TypeZero Technologies, LLC, Beta Bionics, Inc, Insulate Corporation, Diabeloop, and Inreda Diabetic. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Device Type

  • Threshold Suspend Device Systems
  • Control-To-Range (CTR) Systems
  • Control-To-Target (CTT) Systems

By End User

  • Hospitals
  • Clinics
  • Homecare

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Medtronic plc
    • Bigfoot Biomedical, Inc.
    • Johnson & Johnson
    • Tandem Diabetes Care, Inc.
    • Pancreum, Inc
    • TypeZero Technologies, LLC
    • Beta Bionics, Inc
    • Insulate Corporation
    • Diabeloop
    • Inreda Diabetic

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY DEVICE TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Device Type
  • 4.2. Threshold Suspend Device Systems
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Control-To-Range (CTR) Systems
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Control-To-Target (CTT) Systems
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Homecare
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Device Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Artificial Pancreas Devices Systems Market
      • 6.2.5.1. Market Size and Forecast, By Device Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Artificial Pancreas Devices Systems Market
      • 6.2.6.1. Market Size and Forecast, By Device Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Artificial Pancreas Devices Systems Market
      • 6.2.7.1. Market Size and Forecast, By Device Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Device Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Artificial Pancreas Devices Systems Market
      • 6.3.5.1. Market Size and Forecast, By Device Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Artificial Pancreas Devices Systems Market
      • 6.3.6.1. Market Size and Forecast, By Device Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Artificial Pancreas Devices Systems Market
      • 6.3.7.1. Market Size and Forecast, By Device Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Artificial Pancreas Devices Systems Market
      • 6.3.8.1. Market Size and Forecast, By Device Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Artificial Pancreas Devices Systems Market
      • 6.3.9.1. Market Size and Forecast, By Device Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Artificial Pancreas Devices Systems Market
      • 6.3.10.1. Market Size and Forecast, By Device Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Device Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Artificial Pancreas Devices Systems Market
      • 6.4.5.1. Market Size and Forecast, By Device Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Artificial Pancreas Devices Systems Market
      • 6.4.6.1. Market Size and Forecast, By Device Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Artificial Pancreas Devices Systems Market
      • 6.4.7.1. Market Size and Forecast, By Device Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Artificial Pancreas Devices Systems Market
      • 6.4.8.1. Market Size and Forecast, By Device Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Artificial Pancreas Devices Systems Market
      • 6.4.9.1. Market Size and Forecast, By Device Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Artificial Pancreas Devices Systems Market
      • 6.4.10.1. Market Size and Forecast, By Device Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Device Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Artificial Pancreas Devices Systems Market
      • 6.5.5.1. Market Size and Forecast, By Device Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Artificial Pancreas Devices Systems Market
      • 6.5.6.1. Market Size and Forecast, By Device Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Artificial Pancreas Devices Systems Market
      • 6.5.7.1. Market Size and Forecast, By Device Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Artificial Pancreas Devices Systems Market
      • 6.5.8.1. Market Size and Forecast, By Device Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Medtronic Plc
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Bigfoot Biomedical, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Johnson And Johnson
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Tandem Diabetes Care, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Pancreum, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. TypeZero Technologies, LLC
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Beta Bionics, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Insulate Corporation
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Diabeloop
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Inreda Diabetic
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments